-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Candel Therapeutics, Lowers Price Target to $18

Benzinga·11/13/2026 18:28:11
Listen to the news
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $23 to $18.